Discontinuation of dasatinib in patients with Chronic Myelogenous Leukemia-Chronic Phase who have maintained complete molecular remission for at least 1 year.

2 trials

Sponsors

Epidemiological and Clinical Research Information Network (ECRIN), Epidemiological and Clinical Research Information Network(ECRIN)

Conditions

chronic myeloid leukemia

Phase 2

Dasatinib discontinuation for Chronic Myelogenous Leukemia-Chronic Phase with One Year Complete Molecular Remission.

Active, not recruitingJPRN-UMIN000005130

Epidemiological and Clinical Research Information Network (ECRIN)chronic myeloid leukemia

Start: 2011-03-01Target: 50Updated: 2026-06-29

Dasatinib discontinuation for Chronic Myelogenous Leukemia-Chronic Phase with One Year Complete Molecular Remission.

RecruitingJPRN-UMIN000008999

Epidemiological and Clinical Research Information Network(ECRIN)chronic myeloid leukemia

Start: 2012-09-01Target: 50Updated: 2026-06-29

Related Papers

KIR3DL1-HLA-Bw status in CML is associated with achievement of TFR: the POKSTIC trial, a multicenter observational study.

2024-02-093 citations

Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial.

2015-11-10250 citations

Discontinuation Of Dasatinib In Patients With CML Who Have Maintained Complete Molecular Response For At Least One Year: Results From a Prospective Discontinuation (DADI) Trial

Blood2013-11-159 citations